CARDIAC SCAR - Substrates Analysis and Risk Assessment in Arrhythmogenic Cardiomyopathies: the role of CMR

The worldwide rapid evolution and transformation of educational modalities in Medicine is imposing a profound reassessment of teaching and educational methods. 

The Cardiology Division of the University of Padua in Italy has paid considerable attention since ever to innovation in educational processes. On the basis of this historical tradition and profound attention to actual worldwide needs and technological potential it has been decided to organize an innovative virtual congress entitled: “Substrates Analysis and Risk Assessment in Arrhythmogenic Cardiomyopathies: the role of CMR"

Cardiology
Duration:  60 min

Course Description

The worldwide rapid evolution and transformation of educational modalities in Medicine is imposing a profound reassessment of teaching and educational methods. 

The Cardiology Division of the University of Padua in Italy has paid considerable attention since ever to innovation in educational processes. On the basis of this historical tradition and profound attention to actual worldwide needs and technological potential it has been decided to organize an innovative virtual congress entitled: “Substrates Analysis and Risk Assessment in Arrhythmogenic Cardiomyopathies: the role of CMR".

The Course is formed by 9 sessions. Each session is organized as a talk show. Each talk show will last approximately 60 minutes of which 20 devoted to discussion.


Lessons List

  • 1. 1 - ARRHYTHMIC MITRAL VALVE PROLAPSE

    60 min.

    SESSION 1 

    INTRODUCTION: Focus on Mitral Valve Prolapse - S. Iliceto (Padua, Italy)

    Morphological substrates of arrhythmias - M. Perazzolo Marra (Padua, Italy)

    Role of cardiac imaging in the diagnosis - K. Haugaa (Oslo, Norway)

    Arrhythmic risk stratification - F.N. Delling (San Francisco, USA)

    State-of-the-art: Mitral Annular Disjunction - A.P.W. Lee (Hong Kong, China)

    DISCUSSION - S. Iliceto (Padua, Italy) – Panelists

  • 2. LESSON 2 - FOCUS ON ACM

    60 min.

    SESSION 2 

    INTRODUCTION: Focus on ACM - B. Bauce (Padua, Italy)

    Pathological hallmarks - G. Thiene (Padua, Italy)

    CMR: When and Why? - V. Ferrari (Philadelphia, USA)

    CMR and SCD Risk Assessment in ACM - A. Te Riele (Utrecht, The Netherlands)

    State-of-the-art: Updated Diagnostic Criteria - D. Corrado (Padua, Italy)

    DISCUSSION - B. Bauce (Padua, Italy) – Panelists

  • 3. LESSON 3 - DILATED AND INFLAMMATORY CARDIAC DISEASE

    60 min.

    SESSION 3 

    INTRODUCTION: Focus on Inflammatory Cardiac Disease - C. Bucciarelli Ducci (Bristol, United Kingdom)

    Diagnosis? Endomyocardial Biopsy - A.L.P. Caforio (Padova, Italy)

    Diagnosis? CMR is enough - V. Ferreira (Oxford, United Kingdom)

    Prognostic value of tissue characterization - B. Halliday (London, United Kingdom)

    State-of-the-art: Map to the future - M. Friedrich (Calgary, Canada)

    DISCUSSION- C. Bucciarelli Ducci (Bristol, United Kingdom) – Panelists

  • 4. LESSON 4 - HYPERTROPHIC CARDIOMYOPATHY

    60 min.

    INTRODUCTION: Focus on Hypertrophic Cardiomyopathy

    P. Elliott (London, United Kingdom)

    CMR diagnostic features

    M. Maron (Boston, USA)

    Prognostic value of tissue characterization

    S. Neubauer (Oxford, United Kingdom)

    New techniques in CMR

    D. Pennell (London, United Kingdom)

    State-of-the-art: Arrhythmic risk stratification

    W. McKenna (Doha, Qatar/London, United Kingdom)

    DISCUSSION

    P. Elliott (London, United Kingdom) – Panelists

  • 5. LESSON 5 - RARE CARDIOMYOPATHIES

    60 min.

    SESSION 5

    INTRODUCTION: Focus on CMR in Rare Cardiomyopathies - J. Moon (London, United Kingdom)

    CMR in muscular dystrophies - S. Mavrogeni (Athens, Greece)

    CMR in Chagas cardiomyopathy - C.E. Rochitte (Sao Paulo, Brazil)

    CMR in cardiac sarcoidosis - C. Shenoy (Minneapolis, USA)

    State-of-the-art: CMR in cardiac amyloidosis - M. Fontana (London, United Kingdom)

    DISCUSSION - J. Moon (London, United Kingdom) –Panelists

  • 6. LESSON 6 - CORONARY ARTERY DISEASE

    60 min.

    SESSION 6 

    INTRODUCTION: Focus on CMR in coronary artery disease - S. Plein (Leeds, United Kingdom)

    CMR in stress perfusion - R. Kwong (Boston, USA)

    CMR in microvascular injury - C. Berry (Glasgow, United Kingdom)

    CMR in MINOCA - C. Bucciarelli Ducci (Bristol, United Kingdom)

    State-of-the-art: CMR and myocardial viability - P.G. Masci (London UK)

    DISCUSSIONS. Plein (Leeds, United Kingdom) – Panelists

  • 7. SESSION 7- SPORT ACTIVITY AND ARRHYTHMIAS

    60 min.

    INTRODUCTION: Focus on CMR in SCD prevention in athletes

    F. Migliore (Padua, Italy)

    ECG and arrhythmic red flags

    A. Zorzi (Padua, Italy)

    The role of cardiac imaging in sport cardiology

    M. Papadakis (London, UK)

    The role of CMR in the risk assessment

    A. La Gerche (Melbourne, Australia)

    State-of-the-art: Riskstratification for sport activity in cardiomyopathies

    A. Pelliccia (Rome, Italy)

    DISCUSSION      

    F. Migliore (Padua, Italy) – Panelists

  • 8. SESSION 8 - THERAPEUTIC STRATEGIES

    60 min.

    SESSION 8 

    INTRODUCTION: Primary prevention of sudden cardiac death in arrhythmogenic cardiomyopathies -

    G. Boriani (Modena, Italy)

    Primary prevention of sudden cardiac death in non ischemic dilated cardiomyopathies - E. Bertaglia (Padua, Italy)

    The right device in the right patient - F. Migliore (Padua, Italy)

    Long-term outcomes of ablation for ventricular arrhythmias in mitral valve prolapse - F.N. Delling (San Francisco, USA)

    State-of-the-art - Electroanatomic mapping: from arrhytmogenic substrate to therapeutic ablation - P. Della Bella (Milan, Italy)

    DISCUSSION -  G. Boriani (Modena, Italy) – Panelists

  • 9. LESSON 9 - WHEN AND FOR WHOM TO REQUEST CMR?

    60 min.

    SESSION 9 

    INTRODUCTION: the role of CMR in clinical practice - Z. Jing (Beijing, China) – S. Iliceto (Padua, Italy)

    When in mitral valve prolapse?  - R. Bonow (Chicago, USA)

    When in ARVC? - D. Corrado (Padua, Italy)

    When in cardiomyopathies? - R. Sukmawan (Jakarta, Indonesia)

    When in coronary artery disease? - W. El Tahlawy (Abu Dhabi, United Arab Emirates)

    When pathology is still essential? - C. Basso (Padua, Italy)

    State-of-the-art: When echocardiography can avoid CMR? - L.P. Badano (Milan, Italy)

    DISCUSSION Z. Jing (Beijing, China)- S. Iliceto (Padua, Italy) – Panelists